Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Torben F. Hansen"'
Autor:
Paul W. Dempsey, Cristina-Mihaela Sandu, Ricardo Gonzalezirias, Spencer Hantula, Obdulia Covarrubias-Zambrano, Stefan H. Bossmann, Alykhan S. Nagji, Nirmal K. Veeramachaneni, Nezih O. Ermerak, Derya Kocakaya, Tunc Lacin, Bedrittin Yildizeli, Patrick Lilley, Sara W. C. Wen, Line Nederby, Torben F. Hansen, Ole Hilberg
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-9 (2024)
Abstract Background Lung cancer is associated with the greatest cancer mortality as it typically presents with incurable distributed disease. Biomarkers relevant to risk assessment for the detection of lung cancer continue to be a challenge because t
Externí odkaz:
https://doaj.org/article/134d8ce180d04e7ca4d08e080d2e680d
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Robust optimization has been suggested as an approach to reduce the irradiated volume in lung Stereotactic Body Radiation Therapy (SBRT). We performed a retrospective planning study to investigate the potential benefits over Planning Targ
Externí odkaz:
https://doaj.org/article/29c361c4d870455cb5d4689cd4283f9d
Autor:
Liva K. Stuhr, Kasper Madsen, Astrid Z. Johansen, Inna M. Chen, Carsten P. Hansen, Lars H. Jensen, Torben F. Hansen, Kirstine Kløve-Mogensen, Kaspar R. Nielsen, Julia S. Johansen
Publikováno v:
Cancers, Vol 15, Iss 3, p 897 (2023)
The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 us
Externí odkaz:
https://doaj.org/article/fd1a5158185f46409cade94f55767549
Autor:
Ann C. Eriksen, Flemming B. Sørensen, Jan Lindebjerg, Henrik Hager, René dePont Christensen, Sanne Kjær-Frifeldt, Torben F. Hansen
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification. We investigated the prognostic value of Program
Externí odkaz:
https://doaj.org/article/a7a28e1f0129481eac9dc83264f54523
Autor:
Caroline B. Thomsen, Torben F. Hansen, Rikke F. Andersen, Jan Lindebjerg, Lars H. Jensen, Anders Jakobsen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: The early identification of treatment effect is wanted in several settings, including the management of metastatic colorectal cancer (mCRC). A potential universal marker is circulating tumor DNA (ctDNA). Our prospective study explored the
Externí odkaz:
https://doaj.org/article/7691c5fcc85d4275bf673f1042e721cd
Autor:
Ann C. Eriksen, Flemming B. Sørensen, Jan Lindebjerg, Henrik Hager, René dePont Christensen, Sanne Kjær-Frifeldt, Torben F. Hansen
Publikováno v:
Translational Oncology, Vol 11, Iss 4, Pp 979-987 (2018)
BACKGROUND: Additional prognostic markers are needed for better treatment stratification of stage II colon cancer (CC). We investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in a true population-based cohort of patients with s
Externí odkaz:
https://doaj.org/article/a1f28fd18f344843a06c8e19f6b48483
Autor:
Ann C. Eriksen, Johnnie B. Andersen, Jan Lindebjerg, René dePont Christensen, Torben F. Hansen, Sanne Kjær-Frifeldt, Flemming B. Sørensen
Publikováno v:
Diagnostic Pathology, Vol 13, Iss 1, Pp 1-9 (2018)
Abstract Background Tumour budding (TB) and Tumour Stroma Ratio (TSR) may be rewarding in the treatment stratification of patients with stage II colon cancer. However, lack of standardization may exclude these parameters from being used in a clinical
Externí odkaz:
https://doaj.org/article/96043fb106f2497b9ad1a04e751b0edd
Autor:
Kristian Blomberg, Torben F. Hansen, Claus L. Brasen, Jeppe B. Madsen, Lars H. Jensen, Caroline B. Thomsen
Publikováno v:
Cancers, Vol 13, Iss 20, p 5100 (2021)
The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic C
Externí odkaz:
https://doaj.org/article/8d27f079cb97410d8546027cc3781c8c
Autor:
Ann C. Eriksen, Johnnie B. Andersen, Martin Kristensson, René dePont Christensen, Torben F. Hansen, Sanne Kjær-Frifeldt, Flemming B. Sørensen
Publikováno v:
Diagnostic Pathology, Vol 12, Iss 1, Pp 1-14 (2017)
Abstract Background Precise prognostic and predictive variables allowing improved post-operative treatment stratification are missing in patients treated for stage II colon cancer (CC). Investigation of tumor infiltrating lymphocytes (TILs) may be re
Externí odkaz:
https://doaj.org/article/2c335f59e1864b44b6b9cf5135fe466f
Autor:
Sara W. C. Wen, Rikke F. Andersen, Lena Marie S. Petersen, Henrik Hager, Ole Hilberg, Anders Jakobsen, Torben F. Hansen
Publikováno v:
Cancers, Vol 12, Iss 12, p 3728 (2020)
Circulating tumor DNA (ctDNA) has been suggested as a biomarker in non-small cell lung cancer. The optimal target for measuring ctDNA has not yet been established. This study aimed to investigate methylated Homeobox A9 (meth-HOXA9) as an approach to
Externí odkaz:
https://doaj.org/article/ddbc862de1fc4e24b4faf74753ef1770